Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 16, 1997

View Archived Issues

87 development projects under way at Zeneca

New AmBisome data reported

SmithKline Beecham licenses rotavirus vaccine

Faropenem data presented at Japanese congress

Searle describes selective alphav/beta3 integrin antagonists

Natural anti-HIV agent disclosed by Hoechst

ViroPharma develops agents for HCV infection

5-HT receptor (ant)agonists from Pfizer

Selective COX-2 inhibitors under development at Merck Frosst

Second-generation antisense antitumor compound from Hybridon enters clinic

Aronex presents preliminary phase II results on Atragen

Pennsaid submitted to FDA for approval

CerAxon submitted for approval in U.S.

CB1 receptors are activated in hemorrhagic shock

FDA approves new alternative to hysterectomy in women with menorrhagia

Promising results reported from phase II trial for AIDS-related diarrhea

Oral morphine effective for management of sickle cell pain in children

ICAgen and Abbott join forces for ion channel research

Spotlight on ACE inhibitor/calcium antagonist combinations

Sagami discovers lead for potent and selective anti-H. pylori agents

Itraconazole maintenance therapy prevents relapse of histoplasmosis in AIDS

rhIL-11 reduces need for platelet transfusion in breast cancer patients on high-dose chemotherapy

Scherer-Sankyo Zydis formulation agreement

Orally activated protein therapy reported

Elan to acquire Sano in all-stock transaction

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...